Study:
Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Rationale:
n/a
Purpose:
The purpose of this study is to find what effects, good and/or bad, treatment with two drugs
has on leukemia. The first medicine is tretinoin (also called all-trans retinoic acid,
ATRA, or Vesanoid). It is an approved medicine that causes the leukemia cells in APL to
mature. It is related to vitamin A. The second is arsenic trioxide (Trisenox). It is an
approved medicine for APL that comes back after earlier treatment.
APL is most often treated with tretinoin and standard chemotherapy drugs. These
chemotherapy drugs can cause infection and bleeding. They can also damage the heart and
normal bone marrow cells. This can lead to a second leukemia years later.
In this study, the investigators are using tretinoin and arsenic trioxide together. Both
drugs work to treat APL. They have been used together in only a limited number of people.
The investigators want to use these drugs together to reduce the amount of standard
chemotherapy and decrease side effects. The patient will receive standard chemotherapy with
a drug called idarubicin only if they have a higher chance of the leukemia coming back or a
higher risk of side effects.
Study Status: Recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Acute Promyelocytic Leukemia |
Drug: Tretinoin and Arsenic Trioxide |
Phase 2 |
Verified by
Memorial Sloan-Kettering Cancer Center
April, 2013
Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov identifier: NCT01404949
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio 44195
United States
Jae Park, MD., Principal Investigator